KalVista Pharmaceuticals announced that it presented data showing the effectiveness of sebetralstat in reducing anxiety among people experiencing hereditary angioedema (HAE) attacks at the HAEi Global Angioedema Forum (GAF) taking place in Copenhagen, Denmark from 4-5 October 2024. These data were generated in the KONFIDENT phase 3 clinical trial, for which the Company disclosed top line results in February 2024. Sebetralstat is a novel, investigational oral plasma kallikrein inhibitor for the on-demand treatment of HAE attacks in adults and adolescents aged 12 years and older.
William Lumry MD, of Allergy and Asthma Research Associates in the United States, said: “The data presented at the Global Angioedema Forum highlights that people living with HAE often experience substantial anxiety when they have attacks, which reduces quality of life. In KONFIDENT, oral sebetralstat significantly reduced anxiety during attacks compared with placebo, especially among participants with moderate-to-extreme anxiety. If approved, sebetralstat has the potential to become an important option for people living with HAE who experience attack-related anxiety, enabling them to treat early and recover from their attacks sooner.”
Additional poster presentations at the HAEi Global Angioedema Forum 2024:
- Anxiety Associated with Parenteral On-Demand Treatment for Hereditary Angioedema Attacks: Riccardo Senter, Azienda Ospedaliera, Università degli Studi di Padova, Italy
- The Hereditary Angioedema (HAE) Attack Journey: A Conceptual Model of Patient Anxiety and On-Demand Treatment Burden During an HAE Attack: Douglas Jones, Metrodora Institute, Salt Lake City, United States
- Impact of Delayed Treatment of Hereditary Angioedema Attacks on Quality of Life and Ability to Work: Patrick Yong, Frimley Health NHS Foundation Trust, United Kingdom
- Impact of Hereditary Angioedema Attacks on Quality of Life and Ability to Work Among UK Patients Receiving Long-term Prophylaxis or On-demand Treatment Only: Patrick Yong, Frimley Health NHS Foundation Trust, United Kingdom
- Phase 3 KONFIDENT Trial of Oral Sebetralstat for Treatment of Hereditary Angioedema Attacks: Analysis of the European and US Patient Subgroups: Andrea Zanichelli, Operative Unit of Medicine, Angioedema Center, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy; Department of Biomedical Sciences for Health, University of Milan, Italy (Poster presentation)
- Patient-Reported Benefits of Early On-demand Treatment of HAE Attacks: Mar Guilarte, Allergy Department, Hospital Universitari Vall d’Hebron, Spain
- Treatment of HAE Attacks with Anticipated Future Oral On-demand Therapies as Reported by Patients: Anna Valerieva, Department of Allergology, Medical University of Sofia, Bulgaria
- Global Frequency and Diagnosis of Hereditary Angioedema with Normal C1INH: A Real World ACARE Survey: Markus Magerl, Angioedema Center of Reference and Excellence (ACARE), Institute of Allergology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Germany
In Memoriam: KalVista would like to acknowledge and honor the memory of Prof. Marcus Maurer, Professor of Dermatology and Allergy, Executive Director of the Institute of Allergology at the Charité – Universitätsmedizin Berlin, and Co-Director of Allergology and Immunology at the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP. Our thoughts remain with his family and the entire angioedema and urticaria community.
(Source: KalVista)